1. Scrip
  2. >>Focus On Asia
  3. >>India

Abacus acquisition to boost Piramal’s market access capabilities

 
• By Anju Ghangurde

Just over six months after its acquisition of the US-based healthcare information business firm Decision Resources Group (DRG), the Piramal group has added the UK-based Abacus International, a provider of evidence-based global market access solutions, to its fold.

Just over six months after its acquisition of the US-based healthcare information business firm Decision Resources Group (DRG), the Piramal group has added the UK-based Abacus International, a provider of evidence-based global market access solutions, to its fold.

The deal while expanding DRG’s market access capabilities is also expected to boost its position in Europe as a key resource for healthcare firms worldwide

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs